ABSI:NSD-Absci Corp (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.44

Change

+0.11 (+3.30)%

Market Cap

USD 0.32B

Volume

0.25M

Avg Analyst Target

USD 22.00 (+539.53%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ABSI Stock Forecast & Price:
Based on the Absci Corp stock forecasts from 4 analysts, the average analyst target price for Absci Corp is USD 22.00 over the next 12 months. Absci Corp’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Absci Corp is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, Absci Corp’s stock price was USD 3.44. Absci Corp’s stock price has changed by -4.18% over the past week, -5.49% over the past month and 0% over the last year.

About Absci Corp (ABSI:NSD)

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the d ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

+1.66 (+0.58%)

USD73.48B 29.71 20.69
REGN Regeneron Pharmaceuticals Inc

+1.16 (+0.19%)

USD65.40B 8.39 6.44
MRNA Moderna Inc

+5.59 (+3.73%)

USD59.64B 4.20 3.05
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+3.53 (+2.24%)

USD38.28B 2.86 1.54
SGEN Seagen Inc

-3.34 (-1.85%)

USD33.15B 55.02 -51.02
RPRX Royalty Pharma Plc

+0.41 (+0.96%)

USD28.81B 29.89 16.23
GMAB Genmab AS

+0.51 (+1.53%)

USD21.88B 64.29 5.76
ARGX argenx NV ADR

+4.98 (+1.32%)

USD20.88B N/A -31.64
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ABSI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -58.05% 29% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -58.05% 29% F 20% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.32B 66% D 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.91 72% C- 78% C+
Price / Cash Flow Ratio -5.27 69% D+ 72% C-
EV/EBITDA -0.88 52% F 65% D
Management Effectiveness  
Return on Equity -59.25% 48% F 20% F
Return on Invested Capital -46.41% 57% F 21% F
Return on Assets -18.60% 69% D+ 22% F
Debt to Equity Ratio 0.31% 87% B+ 89% B+
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 13.43 9% F 5% F
Short Percent 10.96% 20% F 16% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector